RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Release's 1Q2024 Financial Statements The primary benefits of the Theralase® technology versus competitive technologies are the: urologist-led treatment, single out-patient treatment, high efficacy rates (patients achieve a CR in 58% of the cases after only one Study Procedure), high duration of response (up to 3 years) and high safety margin (no SAEs directly associated with the Study Drug or Study Device); therefore, the Theralase® technology presents a safe, effective alternative therapy for patients, who are at risk of having their bladder removed."
Urologists like this type of procedure treatments which they do themselves and can follow the patients rather than immunotherapy treatments which are done by medical oncologists and not urologists.IMO